Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
san francisco blog main
9
×
san francisco top stories
9
×
boston blog main
national top stories
biotech
boston top stories
san diego blog main
san diego top stories
national
new york blog main
new york top stories
texas blog main
texas top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
wisconsin blog main
wisconsin top stories
cancer
deals
medicare
novartis
venture capital
alnylam pharmaceuticals
amgen
gene therapy
merck
pfizer
roche
What
patients
9
×
drug
bio
roundup
fda
medicine
therapy
cancer
developers
gene
healthcare
help
market
moves
acquisitions
advantages
ago
albert
allison
alnylam
analytics
approve
aren’t
awaits
bar
becker
biggest
billions
biofourmis
biological
bourla
brings
cancers
ceo
company
countless
crispr
crossed
data
daunting
Language
unset
unknown
Current search:
patients
×
" san francisco top stories "
×
" san francisco blog main "
×
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Nobel Medicine Prize Honors Cancer Immunotherapy Pioneers Allison & Honjo
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
Virtual Physical Therapy Firms Reflexion and MindMaze Probe Markets